RCRoland Conradi

Roland Conradi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Roland Conradi has a total of 65 co-authors. Here are the top co-authors by number of shared publications:

  • Claudia Luckner-Minden

    Third Department of Medicine (Hematology, Oncology, and Pneumology), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany

    3 shared publications
  • Guido Wabnitz

    Institute of Immunology, University of Heidelberg, Heidelberg, Germany

    2 shared publications
  • Ingrid Müller

    Department of Medicine, Section of Immunology, Imperial College London, London, United Kingdom

    2 shared publications
  • Markus Munder

    Third Department of Medicine Hematology, Oncology, and Pneumology, University Medical Center Mainz, Mainz, Germany

    2 shared publications
  • Nadja Feldmeyer

    Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany

    2 shared publications
  • Pascale Kropf

    Department of Immunology and Infection, London School of Hygiene and Tropical Medicine, London, United Kingdom

    2 shared publications

Latest Publications

  • Hepatitis E virus genotype 3 is a common finding in liver‐transplanted patients undergoing liver biopsy for elevated liver enzymes with a low De Ritis ratio and suspected acute rejection: A real‐world cohort

    by Felix Darstein, Friederike Häuser, Beate K. Straub, Jürgen J. Wenzel, Roland Conradi, Jens Mittler, Hauke Lang, Peter R. Galle, Tim Zimmermann

    Background: Hepatitis E virus (HEV) infection is a potential reason for elevated liver enzymes after liver transplantation (LT). Our aim was to analyze a real‐world cohort of LT patients, who underwent liver biopsy for elevated transaminases and suspected acute rejection, to evaluate frequency of post‐transplant HEV infection.Patients: Data from 160 liver biopsies were analyzed. Seventy‐one patients were biopsied on schedule after LT without elevated liver enzymes. A subgroup of 25 patients with elevated liver enzymes and suspected rejection was chosen for further analysis. Patient demographics and data were retrieved from a clinical database, patients’ charts, and reports.Results: Hepatitis E virus infection was diagnosed in five of 25 patients with suspected acute rejection (20%). HEV genotype 3 was detected in three of the five HEV‐infected patients. Patients with HEV infection showed higher ALT levels (P = 0.014), lower De Ritis ratio (P = 0.021), and more frequent glucocorticoid therapy (P = 0.012) compared to HEV‐negative patients.Conclusion: We found a rate of 20% HEV infections in LT patients undergoing liver biopsy for elevated liver enzymes and suspected acute rejection. These data indicate the necessity for HEV testing in all LT patients with elevated liver enzymes and suspected acute rejection.


  • Open Access

    Reconstitution of T Cell Proliferation under Arginine Limitation: Activated Human T Cells Take Up Citrulline via L-Type Amino Acid Transporter 1 and Use It to Regenerate Arginine after Induction of Argininosuccinate Synthase Expression

    by Anke Werner, Miriam Koschke, Nadine Leuchtner, Claudia Luckner-Minden, Alice Habermeier, Johanna Rupp, Christin Heinrich, Roland Conradi, Ellen I. Closs, Markus Munder

    In the tumor microenvironment, arginine is metabolized by arginase-expressing myeloid cells. This arginine depletion profoundly inhibits T cell functions and is crucially involved in tumor-induced immunosuppression. Reconstitution of adaptive immune functions in the context of arginase-mediated tumor immune escape is a promising therapeutic strategy to boost the immunological anti-tumor response. Arginine can be recycled in certain mammalian tissues from citrulline via argininosuccinate in a two-step enzymatic process involving the enzymes argininosuccinate synthase (ASS) and argininosuccinate lyase (ASL). Here we demonstrate that anti-CD3/anti-CD28-activated human primary CD4+ and CD8+ T cells upregulate ASS expression in response to low extracellular arginine concentrations, while ASL is expressed constitutively. ASS expression peaked under moderate arginine restriction (20 μM), but no relevant induction was detectable in the complete absence of extracellular arginine. The upregulated ASS correlated with a reconstitution of T cell proliferation upon supplementation of citrulline, while the suppressed production of IFN-γ was refractory to citrulline substitution. In contrast, argininosuccinate reconstituted proliferation and cytokine synthesis even in the complete absence of arginine. By direct quantification of intracellular metabolites we show that activated primary human T cells import citrulline but only metabolize it further to argininosuccinate and arginine when ASS is expressed in the context of low amounts of extracellular arginine. We then clarify that citrulline transport is largely mediated by the L-type amino acid transporter 1 (LAT1), induced upon human T cell activation. Upon siRNA-mediated knockdown of LAT1, activated T cells lost the ability to import citrulline. These data underline the potential of citrulline substitution as a promising pharmacological way to treat immunosuppression in settings of arginine deprivation.


  • Serologic and molecular characterization of weak D type 29

    by Mouna Ouchari, Kshitij Srivastava, Andrea Döscher, Roland Conradi, Saloua Jemni Yacoub, Franz Friedrich Wagner, Willy Albert Flegel


  • Open Access

    Cytotoxicity of Tumor Antigen Specific Human T Cells Is Unimpaired by Arginine Depletion

    by Markus Munder, Melanie Engelhardt, Diana Knies, Sergej Medenhoff, Guido Wabnitz, Claudia Luckner-Minden, Nadja Feldmeyer, Ralf-Holger Voss, Pascale Kropf, Ingrid Müller, et al.

    Tumor-growth is often associated with the expansion of myeloid derived suppressor cells that lead to local or systemic arginine depletion via the enzyme arginase. It is generally assumed that this arginine deficiency induces a global shut-down of T cell activation with ensuing tumor immune escape. While the impact of arginine depletion on polyclonal T cell proliferation and cytokine secretion is well documented, its influence on chemotaxis, cytotoxicity and antigen specific activation of human T cells has not been demonstrated so far. We show here that chemotaxis and early calcium signaling of human T cells are unimpaired in the absence of arginine. We then analyzed CD8+ T cell activation in a tumor peptide as well as a viral peptide antigen specific system: (i) CD8+ T cells with specificity against the MART-1aa26–35*A27L tumor antigen expanded with in vitro generated dendritic cells, and (ii) clonal CMV pp65aa495–503 specific T cells and T cells retrovirally transduced with a CMV pp65aa495–503 specific T cell receptor were analyzed. Our data demonstrate that human CD8+ T cell antigen specific cytotoxicity and perforin secretion are completely preserved in the absence of arginine, while antigen specific proliferation as well as IFN-γ and granzyme B secretion are severely compromised. These novel results highlight the complexity of antigen specific T cell activation and demonstrate that human T cells can preserve important activation-induced effector functions in the context of arginine deficiency.


  • Ischemic-type biliary lesions after liver transplantation: a retrospective analysis of risk factors and outcome.

    by Giancarlo Maccagno, Michael Heise, Maria Hoppe-Lotichius, Veronika Weyer, Roland Conradi, Walter Hitzler

    Ischemic-type biliary lesions (ITBL) are the most troublesome complications after liver transplantation. Their cause remains unknown and, although some risk factors have been identified, results from different research groups are often conflicting. The goal of this study was to investigate potential risk factors for ITBL.


  • Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study

    by Hannes Wandt, Kerstin Schaefer-Eckart, Knut Wendelin, Bettina Pilz, Martin Wilhelm, Markus Thalheimer, Ulrich Mahlknecht, Anthony Ho, Markus Schaich, Michael Kramer, et al.


  • Open Access

    Arginine deficiency leads to impaired cofilin dephosphorylation in activated human T lymphocytes

    by Nadja Feldmeyer, Guido Wabnitz, Stefan Leicht, Claudia Luckner-Minden, Martin Schiller, Thomas Franz, Roland Conradi, Pascale Kropf, Ingrid Müller, Anthony D. Ho, et al.

    The amino acid arginine is fundamentally involved in the regulation of the immune response during infection, inflammatory diseases and tumor growth. Arginine deficiency (e.g. due to the myeloid cell enzyme arginase) inhibits proliferation and effector functions of activated T lymphocytes. Here, we studied intracellular mechanisms mediating this suppression of human T lymphocytes. Our proteomic analysis revealed an impaired dephosphorylation of the actin-binding protein cofilin upon T-cell activation in the absence of arginine. We show that this correlates with alteration of actin polymerization and impaired accumulation of CD2 and CD3 in the evolving immunological synapse in T cell–antigen presenting cells conjugates. In contrast, T-cell cytokine synthesis is differentially regulated in human T lymphocytes in the absence of arginine. While the production of certain cytokines (e.g. IFN-γ) is severely reduced, T lymphocytes produce other cytokines (e.g. IL-2) independent of extracellular arginine. MEK and PI3K activity are reciprocally regulated in association with impaired cofilin dephosphorylation. Finally, we show that impaired cofilin dephosphorylation is also detectable in human T cells activated in a granulocyte-dominated purulent micromilieu due to arginase-mediated arginine depletion. Our novel results identify cofilin as a potential regulator of human T-cell activation under conditions of inflammatory arginine deficiency.